FOOD AND DRUG ADMINISTRATION
CENTER
FOR DRUG EVALUATION AND RESEARCH (CDER)
Chair, Endocrinologic and Metabolic Drugs Advisory
Committee
Conflict of Interest
Statement Dornette
Spell-LeSane, M.H.A., NP-C
Executive
Secretary, EMDAC
Director
Division
of Metabolic and Endocrine
Drug Products, FDA
__________________________________________________________________________________________
NDA 21-366 Crestor® (rosuvastatin calcium) tablets, AstraZeneca
Pharmaceuticals agent for
iPR
Pharmaceuticals, Inc.
Proposed for the indication
of treatment of hypercholesterolemia and mixed dyslipidemia
Introduction
and Mark
S. Eliason, M.Sc.
Regulatory
Overview Director,
Regulatory Affairs
AstraZeneca
Clinical
Development James
W. Blasetto, M.D., M.P.H.
Efficacy
Overview Senior
Medical Director
AstraZeneca
Clinical
Development Howard
G. Hutchinson, M.D.
Safety
Overview Vice
President, Clinical Research
AstraZeneca
Endocrinologic
and Metabolic Drugs Advisory Committee
Meeting
Agenda (cont.)
Sponsor Presentation Cont.
The
Role of Rosuvastatin in the Daniel
J. Rader, M.D.
Treatment
of Hyperlipidemia Associate
Program Director
Efficacy Joy
Mele, M.S.
Statistical Reviewer
Division of Biometrics II
Office of Biostatistics, FDA
Safety
and Dosing William
Lubas, M.D.
Medical
Officer
Division
of Metabolic and Endocrine
Drug
Products, FDA
Director
Division of Metabolic and
Endocrine
Drug Products, FDA